Blockade of BRAFi-induced autophagy–lysosomal activation in BRAF-mutant melanoma causes increased tumor progression, epithelial-to-mesenchymal-like transition (EMT), and partial resistance to BRAFi therapy. Here, BRAF is linked to melanoma.